Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Terrance Mcguire sold 65,359 shares of the company's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $0.47, for a total value of $30,718.73. Following the completion of the transaction, the director now directly owns 4,012,320 shares in the company, valued at $1,885,790.40. The trade was a 1.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Terrance Mcguire also recently made the following trade(s):
- On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
- On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.
Invivyd Stock Down 17.6 %
Shares of Invivyd stock opened at $0.45 on Tuesday. Invivyd, Inc. has a 12-month low of $0.45 and a 12-month high of $5.20. The company has a market capitalization of $53.89 million, a price-to-earnings ratio of -0.23 and a beta of 0.53. The firm's 50-day moving average price is $0.82 and its two-hundred day moving average price is $1.05.
Wall Street Analyst Weigh In
We recommended Palantir in 2021, now we’re recommending this...
From Behind the Markets | Ad
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
Click to get the name and ticker symbol
A number of equities research analysts have recently issued reports on the stock. HC Wainwright decreased their price target on shares of Invivyd from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, November 20th. Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an "overweight" rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a "strong-buy" rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $7.89.
View Our Latest Analysis on Invivyd
Institutional Trading of Invivyd
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Proficio Capital Partners LLC bought a new position in Invivyd in the third quarter valued at approximately $27,000. XTX Topco Ltd increased its stake in shares of Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company's stock valued at $42,000 after purchasing an additional 15,376 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company's stock worth $42,000 after buying an additional 25,201 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new stake in Invivyd in the second quarter valued at about $86,000. Finally, Rhumbline Advisers grew its position in Invivyd by 4,434.1% in the second quarter. Rhumbline Advisers now owns 84,017 shares of the company's stock valued at $92,000 after acquiring an additional 82,164 shares during the last quarter. Institutional investors own 70.36% of the company's stock.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
